Healthcare-focussed investment firm OrbiMed Asia has signed definitive agreements with NSE-listed Vivimed Labs Limited, a pharmaceuticals and specialty chemicals company, for an investment of $42.5 million into the latter’s subsidiary Vivimed Labs Mascarene Ltd.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
